Article
Health Care Sciences & Services
Paschalis Steiropoulos, Stavros Tryfon, Christos Kyriakopoulos, Konstantinos Bartziokas, Konstantinos Kostikas
Summary: The study found that COPD patients treated with SFC via the Elpenhaler® device showed significant improvement in lung function and dyspnea at 6 and 12 months, irrespective of the presence of comorbidities.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Respiratory System
Santhalingam Balamurugan, Dalal Sonia, Deshmukh Vikrant, Khanra Monotosh, Sundar Raj Shyam, Akhtar Shamim, Kumar Vinay, Nandagopal Velayuthaswamy, Ahmed Masood, Gupta Manohar Lal, Godse Ajay, Chhowala Sushmeeta, Lopez Meena, Sawant Sandesh, Jadhav Sonali, Vaidya Abhijit, Gogtay Jaideep
Summary: This study evaluated asthma control and device usability in Indian patients with persistent asthma using salmeterol/fluticasone fixed-dose combination (FDC) administered through the breath-actuated inhaler, Synchrobreathe((R)). The results showed that this treatment improved asthma control and lung function for 12 weeks and was well tolerated by patients. Most patients were satisfied with the Synchrobreathe((R)) inhaler and preferred it over their previous device.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
(2022)
Article
Allergy
Nicolas Roche, Bernard Aguilaniu, Simon Paternotte, Nathalie Dallery
Summary: Switching to DuoResp (R) Spiromax (R) can reduce levels of inadequately controlled or uncontrolled asthma, with a high patient satisfaction rate. Concurrent illness may contribute to device handling errors, highlighting the importance of regularly assessing inhaler technique and patient device satisfaction.
Article
Respiratory System
Ines Vinge, Jorgen Syk, Athanasios Xanthopoulos, Hendrik Lassmann, Mikko Vahteristo, Ulla Sairanen, Satu Lahelma, Rudolf Hennig, Matthias Muller
Summary: The study found that for asthma and COPD patients switching from another S/F inhaler to S/F Easyhaler, the effectiveness was better or at least similar, patients preferred Easyhaler, and it was easy to teach, learn, and use in a real-life setting.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
(2021)
Article
Allergy
Xiaofen Jin, Lianfang Wu, Ji Wang, Malong Feng
Summary: The meta-analysis found that for pediatric asthma, FP/FORM and FP/SAL have similar efficacy in terms of FEV1, FVC, lung function, and symptom scores.
POSTEPY DERMATOLOGII I ALERGOLOGII
(2021)
Article
Medicine, General & Internal
Sergey K. Zyryanov, Ilya N. Dyakov, Zaurbek R. Aisanov
Summary: Using budesonide + formoterol (Symbicort (R) Turbuhaler (R)) as maintenance therapy for asthma can significantly reduce healthcare costs and prevent asthma exacerbations.
TERAPEVTICHESKII ARKHIV
(2022)
Review
Medicine, General & Internal
Orlagh O'Shea, Elizabeth Stovold, Christopher J. Cates
Summary: Studies have shown that long-acting beta-agonists like formoterol and salmeterol used to treat chronic asthma can increase the risk of serious adverse events compared to a placebo. However, there is still debate on the safety of combining long-acting beta-agonists with inhaled steroids, as different research results are conflicting.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Biochemistry & Molecular Biology
Suharsh Shah, Mahmoud M. Mostafa, Andrew McWhae, Suzanne L. Traves, Robert Newton
JOURNAL OF BIOLOGICAL CHEMISTRY
(2016)
Article
Pharmacology & Pharmacy
Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton, Mark A. Giembycz
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2017)
Review
Biochemistry & Molecular Biology
Robert Newton, Suharsh Shah, Mohammed O. Altonsy, Antony N. Gerber
JOURNAL OF BIOLOGICAL CHEMISTRY
(2017)
Article
Multidisciplinary Sciences
Tresa George, Matthew Bell, Mainak Chakraborty, David P. Siderovski, Mark A. Giembycz, Robert Newton
Article
Allergy
Ryan D. Huff, Christopher F. Rider, Dong Yan, Robert Newton, Mark A. Giembycz, Chris Carlsten, Jeremy A. Hirota
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2018)
Article
Pharmacology & Pharmacy
Dong Yan, Omar Hamed, Taruna Joshi, Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, Mark A. Giembycz
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2018)
Article
Pharmacology & Pharmacy
Christopher F. Rider, Mohammed O. Altonsy, Mahmoud M. Mostafa, Suharsh Shah, Sarah Sasse, Martijn L. Manson, Dong Yan, Carina Karrman-Mardh, Anna Miller-Larsson, Anthony N. Gerber, Mark A. Giembycz, Robert Newton
MOLECULAR PHARMACOLOGY
(2018)
Article
Genetics & Heredity
Mahmoud M. Mostafa, Christopher F. Rider, Suharsh Shah, Suzanne L. Traves, Paul M. K. Gordon, Anna Miller-Larsson, Richard Leigh, Robert Newton
BMC MEDICAL GENOMICS
(2019)
Article
Pharmacology & Pharmacy
Radhika Joshi, Dong Yan, Omar Flamed, Mahmoud M. Mostafa, Taruna Joshi, Robert Newton, Mark A. Giembycz
MOLECULAR PHARMACOLOGY
(2019)
Article
Pharmacology & Pharmacy
Mahmoud M. Mostafa, Christopher F. Rider, N. Dulmini Wathugala, Richard Leigh, Mark A. Giembycz, Robert Newton
Summary: In 2019, asthma treatment guidelines recommended ICS/LABA combination therapy as a first-line treatment option. The study found that formoterol and budesonide induced gene expression changes in BEAS-2B and pHBECs cells, with the combination of both drugs leading to more gene induction and repression compared to individual treatments.
MOLECULAR PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Mahmoud M. Mostafa, Akanksha Bansal, Aubrey N. Michi, Sarah K. Sasse, David Proud, Anthony N. Gerber, Robert Newton
Summary: The ligand-activated glucocorticoid receptor (GR) can induce variable responses in different cell types, but certain genes like KLF9 show conserved responses. Through experiments and sequencing, it was found that glucocorticoids induce KLF9 expression through multiple specific binding sites, with interactions between these sites and the transcription start site correlating with KLF9 induction. Mechanistic insights gained from cell lines were shown to translate to physiologically relevant systems, highlighting the importance of understanding the regulatory mechanisms of glucocorticoid-mediated gene expression.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Review
Biochemistry & Molecular Biology
Anthony N. Gerber, Robert Newton, Sarah K. Sasse
Summary: Studies have shown that glucocorticoids achieve transcriptional repression through a two-part model, initially by rapidly inhibiting the transcription of inflammatory genes through GR-mediated transcriptional induction, and then by a subset of GR-induced genes exerting a secondary repressive effect on inflammatory gene expression.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Article
Pharmacology & Pharmacy
Radhika Joshi, Omar Hamed, Dong Yan, Aubrey N. Michi, Mahmoud M. Mostafa, Shahina Wiehler, Robert Newton, Mark A. Giembycz
Summary: This study suggests that targeting EP4-receptor activation in human bronchial epithelial cells can promote gene expression changes that may provide therapeutic benefits for individuals with asthma, COPD, and IPF where current treatment options are inadequate.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2021)
Article
Allergy
Tresa George, Mainak Chakraborty, Mark A. Giembycz, Robert Newton
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
(2018)
Article
Physiology
Mohammed O. Altonsy, Mahmoud M. Mostafa, Anthony N. Gerber, Robert Newton
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
(2017)